News

Immunization with MV140 effective against uropathogens

May 2024

The journal Vaccines publishes an experimental study with MV140, a mucosal bacterial vaccine developed by INMUNOTEK for the prevention of recurrent urinary tract infections. The results demonstrate the ability of MV140 to induce an immune response against uropathogenic E coli (UPEC) strains not included in MV140 and to provide protection in urinary tract infection models.
More info

Impact of MV140 in Interstitial Cystitis

May 2024

Pathogens publishes the positive effect of MV140 in women with interstitial cystitis/painful bladder syndrome refractory to conventional treatment. These patients were a subgroup of the cohort of subjects included in the first clinical trial conducted in North America (Canada) to assess the effect of MV140 on recurrent uncomplicated urinary tract infections.
More info

EAU 2024: Long-term MV140 results presented

April 2024

Long-term (9-year) follow-up results of patients treated with MV140 for the prevention of recurrent urinary tract infections were presented at the annual congress of the European Society of Urology in Paris. The results, presented by Dr. Yang (Royal Berkshire NHS Foundation Trust, United Kingdom), indicate durable effects over this period, with sustained clinical benefit in a large percentage of these patients.
More info

CAR-T cell immunotherapy against solid tumors, a review

April 2024

The journal Cells publishes a review on the current status of cancer immunotherapy based on CAR-T cells, cytotoxic lymphocytes modified in their antigen recognition receptor. The review updates the challenges of this therapy for solid tumors and the potential of tumor carbohydrates as universal targets for different types of cancer.
More info

MV140 and quality of life in recurrent urinary tract infections

March 2024

According to data published in the journal European Urology Open Science, the quality of life of patients with recurrent urinary tract infections who have been treated for three months with MV140 improves with respect to the control group. This improvement is associated with a reduction in the number of days of infection and antibiotic consumption.
More info

MV130 in recurrent respiratory infections: a real-life study

February 2024

Vaccines publishes a study using real-life data to evaluate the incidence of respiratory infections and antibiotic consumption in patients treated with MV130. The study demonstrates a significant reduction in upper and lower respiratory tract infections and antibiotic consumption in both adults and children.
More info

Dust mite allergy: a 360º approach

February 2024

Frontiers in Allergy publishes the approach to the house dust mite allergy patient from a perspective that integrates molecular diagnostic tools with different treatment options for optimal diagnosis and treatment.
More info

MV140 reduces recurrent UTIs in North American women

February 2024

According to a Canadian study published in the Canadian Urolological Association Journal, MV140 reduces the number of urinary tract infections (UTI) in women with recurrent cystitis. MV140 had demonstrated its efficacy against this type of infection in studies carried out in Europe (Spain and the United Kingdom). The one now published is the first to be carried out in women in North America.
More info

Mosquito allergy review

December 2023

Mosquito allergy is important in certain geographical areas where the population density of these insects is high. Molecular Immunology publishes an interesting review on the different forms of allergic reactions caused by mosquitoes.
More info

Mite sensitization profile by molecular diagnostics

December 2023

The sensitization profile to house dust mites was studied in young allergic subjects with different clinical situations (rhinitis, asthma and atopic dermatitis). The results were published in Current Issues of Biological Medicine.
More info